Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany.
Aging
Cognitive decline
Cognitive impairment
Database research study
Metabolic inflammation
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
01
07
2020
accepted:
28
09
2020
pubmed:
11
10
2020
medline:
30
9
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
Dementia and NAFLD are two frequent conditions that share underlying risk factors mainly in the realm of metabolic disease. Additionally, an association between NAFLD and brain aging has been proposed. Therefore, we investigated the hypothesis if NAFLD is an independent risk factor for emerging dementia. In this population-based cohort study, elderly patients (≥ 65 years) with NAFLD diagnosed between 2000 and 2015 were matched 1:1 to a cohort without NAFLD based on ICD-10 coding in the Disease Analyzer database. Matching criteria were age, sex, physician, index year, and co-diagnoses associated with dementia. The primary outcomes of this study were all-cause dementia diagnoses, the incidence of vascular dementia, and antidementive drug prescription. A total of 22,317 patients with NAFLD were matched to 22,317 patients without NAFLD. Within 10 years of the index date, 16.0% of patients with NAFLD and 15.6% of the patients without NAFLD were diagnosed with dementia. On Cox regression analysis, there is no association between NAFLD and the incidence of all-cause dementia (HR 0.97, 95% CI 0.92-1.04), vascular dementia (HR 0.89, 95% CI 0.78-1.02), or the new prescription of antidementive therapy (HR 0.87, 95% CI 0.76-1.01). In sensitivity analyses, there was no association between NAFLD and dementia in different age-groups as well as men or women. In conclusion, in this database study of elderly patients coded with NAFLD no independent association with incident dementia was detected. Risk assessment regarding dementia in patients with NAFLD should be carried out in the same way as for metabolic burdened patients.
Identifiants
pubmed: 33037968
doi: 10.1007/s10620-020-06644-1
pii: 10.1007/s10620-020-06644-1
pmc: PMC8379104
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3179-3185Informations de copyright
© 2020. The Author(s).
Références
BMC Med. 2019 Jul 4;17(1):123
pubmed: 31269936
Eur J Neurol. 2015 Dec;22(12):1519-25
pubmed: 24910016
Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1
pubmed: 30580090
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):377-379
pubmed: 32514153
Gastroenterology. 2020 May;158(7):1929-1947.e6
pubmed: 32068022
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76
pubmed: 23855299
Gastroenterol Hepatol Bed Bench. 2018 Winter;11(1):27-33
pubmed: 29564062
BMC Med. 2019 May 20;17(1):95
pubmed: 31104631
Curr Opin Lipidol. 2011 Dec;22(6):479-88
pubmed: 22002020
JAMA Netw Open. 2019 Jul 3;2(7):e197978
pubmed: 31365104
Br J Anaesth. 2018 May;120(5):969-977
pubmed: 29661414
J Neuroinflammation. 2016 Jan 05;13:1
pubmed: 26728181
Gastroenterology. 2020 May;158(7):1899-1912
pubmed: 32061598
United European Gastroenterol J. 2020 Oct;8(8):942-948
pubmed: 32698692
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Hepatol Commun. 2019 Sep 30;3(11):1472-1481
pubmed: 31701071
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Gastroenterology. 2020 May;158(7):1849-1850
pubmed: 32302525
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Gastroenterology. 2020 May;158(6):1611-1625.e12
pubmed: 32027911
Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116
pubmed: 30288767
JAMA Neurol. 2018 Jan 1;75(1):97-104
pubmed: 29159396
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Liver Int. 2019 Sep;39(9):1713-1721
pubmed: 31155826
Front Aging Neurosci. 2014 May 20;6:93
pubmed: 24904407
Front Aging Neurosci. 2019 Jul 17;11:174
pubmed: 31379558
Dig Dis Sci. 2020 Jul;65(7):2112-2119
pubmed: 31797186
Medicine (Baltimore). 2016 Apr;95(16):e3446
pubmed: 27100443